公开(公告)号：US11896618B2

公开(公告)日：2024-02-13

申请号：US16992511

申请日：2020-08-13

申请人： Shattuck Labs, Inc.

发明人： Taylor Schreiber ,  George Fromm ,  Suresh De Silva

IPC分类号： C07K14/705 ,  C07K19/00 ,  A61K35/17 ,  C07K14/725 ,  C12N5/0783 ,  C07K16/22

CPC分类号： A61K35/17 ,  C07K14/7051 ,  C07K14/7056 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/22 ,  C12N5/0636 ,  C07K2317/53 ,  C07K2319/03

摘要： The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.

公开(公告)号：US11884716B2

公开(公告)日：2024-01-30

申请号：US17543429

申请日：2021-12-06

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Saar Gill ,  Jonathan Hogan ,  Aimee S. Payne ,  Baomei Wang

IPC分类号： C07K16/18 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725

CPC分类号： C07K14/7056 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K2319/02 ,  C07K2319/03

摘要： The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

公开(公告)号：US20240018197A1

公开(公告)日：2024-01-18

申请号：US18464507

申请日：2023-09-11

申请人： INSTITUT CURIE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： Franck PEREZ ,  Zelia GOUVEIA ,  Gaelle BONCOMPAIN

IPC分类号： C07K14/36 ,  C07K14/725 ,  C07K14/74 ,  C07K14/705 ,  C12N15/63

CPC分类号： C07K14/36 ,  C07K14/7051 ,  C07K14/70539 ,  C07K14/7056 ,  C12N15/63 ,  C07K2319/04 ,  C07K2319/10

摘要： A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.

公开(公告)号：US20230338531A1

公开(公告)日：2023-10-26

申请号：US18021519

申请日：2021-08-20

申请人： City of Hope

发明人： Zhiqiang Wang ,  Christine E. Brown ,  Stephen J. Forman

IPC分类号： A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C07K14/73 ,  C07K14/705 ,  C07K14/715 ,  A61P35/00 ,  C12N15/11 ,  C12N9/22 ,  C12N15/90

CPC分类号： A61K39/4631 ,  C07K14/7051 ,  C07K16/289 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/7056 ,  C07K14/7151 ,  C07K14/70503 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4633 ,  A61K39/4632 ,  A61P35/00 ,  C12N15/11 ,  C12N9/22 ,  C12N15/907 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/02 ,  C12N2310/20 ,  C12N2800/80

摘要： Immune cells, including T cells, expressing a chimeric antigen receptor targeted to CD45 are described. In some cases, the immune cells lack a functional CD45 gene. In some cases, the immune cells also include a modification (a suicide sequence) that allows the cells to be killed in vivo. The immune cells are useful for treating a variety of cancers.

公开(公告)号：US20230287111A1

公开(公告)日：2023-09-14

申请号：US18054223

申请日：2022-11-10

申请人： 2seventy bio, Inc.

发明人： Jordan Jarjour ,  Alexander Astrakhan ,  Michael Certo

IPC分类号： C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K14/735 ,  C12N9/06 ,  C12N9/16 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  C07K16/40 ,  C12N9/12 ,  C12N9/90 ,  C12N15/85

CPC分类号： C07K16/2803 ,  A61K35/17 ,  A61K39/0005 ,  A61K45/06 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/2896 ,  C07K16/40 ,  C12N9/003 ,  C12N9/12 ,  C12N9/16 ,  C12N9/90 ,  C12N15/85 ,  C12Y207/11001 ,  C12Y502/01008 ,  C07H21/04 ,  C12N2510/00

摘要： The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.

公开(公告)号：US20230220048A1

公开(公告)日：2023-07-13

申请号：US17640295

申请日：2020-09-04

申请人： NOVARTIS AG

发明人： Sebastien IRIGARAY ,  Laurent KLEIN ,  Darko SKEGRO ,  Marco VILLANI ,  Karl WELZENBACH

IPC分类号： C07K14/765 ,  C07K14/485 ,  C07K14/705

CPC分类号： C07K14/765 ,  C07K14/485 ,  C07K14/7056 ,  C07K2319/30 ,  C07K2319/31 ,  A61K38/00

摘要： The present invention relates to fusion proteins suitable for use as a medicament or research tool. Therapeutic uses of the fusion proteins may include the prevention or treatment of acute or chronic inflammatory and immune system-driven organ and micro-vascular disorders, for example, acute kidney injury, acute myocardial infarction, acute respiratory distress or chronic obstructive pulmonary disease fibrosis and other organ injuries resulting from tissue trauma and acute and chronic injury.

公开(公告)号：US20230172171A1

公开(公告)日：2023-06-08

申请号：US17922692

申请日：2021-05-21

申请人： Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

发明人： Yuelei Shen ,  Yang Bai ,  Chaoshe Guo ,  Meiling Zhang ,  Rui Huang ,  Chengzhang Shang

IPC分类号： A01K67/027 ,  A61K49/00 ,  C07K14/705 ,  C12N15/90

CPC分类号： A01K67/0278 ,  A61K49/0008 ,  C07K14/7056 ,  C07K14/70596 ,  C12N15/907 ,  A01K2217/15 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  C12N2015/8527

摘要： The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD94 and/or NKG2A, and methods of use thereof.

公开(公告)号：US20180371051A1

公开(公告)日：2018-12-27

申请号：US15775298

申请日：2016-11-10

申请人： Fred Hutchinson Cancer Research Center

发明人： Roland K. Strong ,  Mesfin Gewe ,  Martin Prlic ,  Peter Rupert ,  Thomas Spies ,  Veronika Spies

IPC分类号： C07K14/705 ,  C07K14/47 ,  A61P35/00 ,  A61K39/39

CPC分类号： C07K14/7056 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/55516 ,  A61P35/00 ,  C07K14/47 ,  C07K14/4705 ,  C07K16/2833 ,  C07K16/2851 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/43 ,  C07K2319/50 ,  C07K2319/70 ,  C07K2319/74

摘要： Single chain, multimerized, and/or glycosylated NKG2D decoys are described. The NKG2D decoys have high affinity and avidity for surface bound and soluble NKG2D ligands and can be used to (i) identify NKG2D ligands; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses.

公开(公告)号：US20180355013A1

公开(公告)日：2018-12-13

申请号：US15775568

申请日：2016-11-11

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Glenn Dranoff ,  Ryan Sullivan ,  Matthew Vanneman

IPC分类号： C07K14/705 ,  C07K14/54 ,  A61P35/00 ,  A61K45/06 ,  A61K38/20 ,  A61K38/17

CPC分类号： C07K14/7056 ,  A61K38/178 ,  A61K38/2086 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/00 ,  C07K14/5443 ,  C07K14/705 ,  C07K14/70596 ,  C07K19/00 ,  C07K2319/30

摘要： Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.

公开(公告)号：US20180193452A1

公开(公告)日：2018-07-12

申请号：US15084192

申请日：2016-03-29

申请人： THE NEMOURS FOUNDATION

发明人： Zhengyu Ma

IPC分类号： A61K39/395 ,  C12N5/0783 ,  C07K16/28

CPC分类号： A61K39/3955 ,  C07K14/7051 ,  C07K14/70535 ,  C07K14/7056 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/14 ,  C07K2317/52 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C12N5/0636

摘要： A chimeric antigen receptor (CAR) contains a human FcεRIα extracellular domain or a mutant FcεRIα extracellular domain that has a reduced binding affinity for human IgE compared to wild type human FcεRIα extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.